A Phase 1 interventional study of B/F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 8 sites in 3 countries. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2024-06-14.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the steady state PK of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected, virologically suppressed pregnant women in their second and third trimesters.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women participants will receive fixed dose combination (FDC) tablet of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for up to 38 weeks (from the second or third trimesters of pregnancy, depending on enrollment, through 12 weeks post-partum).
Drug: B/F/TAF
Neonates who will be born to women participants in the study will be followed from birth up to 8 weeks of age after obtaining consent from the parent or legal guardian. None of the neonates that participate in the study will be treated with the study drug.
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablet administered orally once daily without regard to food.
Also known as: GS-9883/F/TAF, Biktarvy®, BVY
Pharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC)
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: AUCtau of Emtricitabine (FTC) and Tenofovir Alafenamide (TAF)
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: AUClast of BIC, FTC, and TAF
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: Cmax of BIC, FTC, and TAF
Cmax is defined as the maximum observed concentration of drug during the dosing interval.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: Ctau of BIC and FTC
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: Clast of BIC, FTC, and TAF
Clast is defined as the last observable concentration of drug.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: Tmax of BIC, FTC, and TAF
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: t1/2 of BIC, FTC, and TAF
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: CLss/F of BIC, FTC, and TAF
CLss/F is defined as the apparent steady-state oral clearance following administration of the drug.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: Vz/F of BIC, FTC, and TAF
Vz/F is defined as the apparent volume of distribution of the drug.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
PK Parameter: λz of BIC, FTC, and TAF
λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
Time frame: Intensive PK: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in second trimester (Weeks 20-28), third trimester (Weeks 30-38), Week 6 post-partum, and Week 12 post-partum
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at the Time of Delivery Using the Missing = Excluded Approach in B/F/TAF Group
The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of delivery was analyzed in B/F/TAF group using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
Time frame: At time of delivery
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Birth Using the Missing = Excluded Approach in Neonates
The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of birth was analyzed in neonates using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
Time frame: At birth
Participants were enrolled at study sites in the Dominican Republic, Thailand and the United States.
| Milestone | B/F/TAF | Neonates |
|---|---|---|
| Started | 33 | 29 |
| Completed | 32 | 29 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| hours*nanograms per milliliter (h*ng/mL) | B/F/TAF |
|---|---|
| Second Trimester | 62772.2 ± 20242.18 |
| Third Trimester | 60163.4 ± 17482.06 |
| Week 6 Post-partum | 134820.3 ± 36217.30 |
| Week 12 Post-partum | 148251.6 ± 42189.17 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | B/F/TAF |
|---|---|
| FTC: Second Trimester | 10263.8 ± 2054.35 |
| FTC: Third Trimester | 10435.2 ± 2121.87 |
| FTC: Week 6 Post-partum | 16277.5 ± 4023.42 |
| FTC: Week 12 Post-partum | 15308.5 ± 3359.83 |
| TAF: Second Trimester | 235.5 ± 107.36 |
| TAF: Third Trimester | 212.1 ± 95.38 |
| TAF: Week 6 Post-partum | 374.3 ± 153.54 |
| TAF: Week 12 Post-partum | 296.4 ± 94.37 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| h*ng/mL | B/F/TAF |
|---|---|
| BIC: Second Trimester | 63187.5 ± 19814.99 |
| BIC: Third Trimester | 60145.3 ± 17484.52 |
| BIC: Week 6 Post-partum | 135058.9 ± 36348.21 |
| BIC: Week 12 Post-partum | 148265.3 ± 42201.47 |
| FTC: Second Trimester | 10258.5 ± 2049.53 |
| FTC: Third Trimester | 10434.2 ± 2121.13 |
| FTC: Week 6 Post-partum | 16329.7 ± 4095.44 |
| FTC: Week 12 Post-partum | 15308.5 ± 3359.79 |
| TAF: Second Trimester | 220.4 ± 98.98 |
| TAF: Third Trimester | 202.2 ± 84.98 |
| TAF: Week 6 Post-partum | 356.7 ± 151.27 |
| TAF: Week 12 Post-partum | 294.3 ± 97.88 |
Cmax is defined as the maximum observed concentration of drug during the dosing interval.
| ng/mL | B/F/TAF |
|---|---|
| BIC: Second Trimester | 5819.0 ± 1752.29 |
| BIC: Third Trimester | 5374.7 ± 1393.86 |
| BIC: Week 6 Post-partum | 9765.5 ± 2274.93 |
| BIC: Week 12 Post-partum | 11025.3 ± 2747.42 |
| FTC: Second Trimester | 2639.1 ± 965.60 |
| FTC: Third Trimester | 2586.0 ± 686.42 |
| FTC: Week 6 Post-partum | 3394.8 ± 951.83 |
| FTC: Week 12 Post-partum | 3360.0 ± 902.47 |
| TAF: Second Trimester | 332.4 ± 173.29 |
| TAF: Third Trimester | 270.9 ± 113.93 |
| TAF: Week 6 Post-partum | 506.4 ± 249.33 |
| TAF: Week 12 Post-partum | 494.6 ± 259.51 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | B/F/TAF |
|---|---|
| BIC: Second Trimester | 1046.4 ± 472.68 |
| BIC: Third Trimester | 1072.4 ± 447.03 |
| BIC: Week 6 Post-partum | 3530.3 ± 1354.20 |
| BIC: Week 12 Post-partum | 3641.9 ± 1241.64 |
| FTC: Second Trimester | 59.8 ± 62.17 |
| FTC: Third Trimester | 51.4 ± 13.98 |
| FTC: Week 6 Post-partum | 152.1 ± 271.50 |
| FTC: Week 12 Post-partum | 81.1 ± 27.34 |
Clast is defined as the last observable concentration of drug.
| ng/mL | B/F/TAF |
|---|---|
| BIC: Second Trimester | 1141.10 ± 631.431 |
| BIC: Third Trimester | 1075.13 ± 447.847 |
| BIC: Week 6 Post-partum | 3535.48 ± 1371.162 |
| BIC: Week 12 Post-partum | 3641.88 ± 1240.605 |
| FTC: Second Trimester | 75.08 ± 130.792 |
| FTC: Third Trimester | 51.65 ± 14.182 |
| FTC: Week 6 Post-partum | 156.16 ± 292.579 |
| FTC: Week 12 Post-partum | 81.18 ± 27.334 |
| TAF: Second Trimester | 4.49 ± 5.130 |
| TAF: Third Trimester | 4.80 ± 4.048 |
| TAF: Week 6 Post-partum | 3.13 ± 1.849 |
| TAF: Week 12 Post-partum | 3.36 ± 1.999 |
Tmax is defined as the time (observed time point) of Cmax.
| h | B/F/TAF |
|---|---|
| BIC: Second Trimester | 2.00 (1.00 to 12.00) |
| BIC: Third Trimester | 2.00 (1.00 to 6.00) |
| BIC: Week 6 Post-partum | 1.50 (0.50 to 12.00) |
| BIC: Week 12 Post-partum | 1.50 (0.50 to 4.00) |
| FTC: Second Trimester | 1.50 (0.50 to 4.00) |
| FTC: Third Trimester | 1.50 (0.50 to 4.00) |
| FTC: Week 6 Post-partum | 1.50 (0.50 to 4.00) |
| FTC: Week 12 Post-partum | 1.00 (0.50 to 3.00) |
| TAF: Second Trimester | 0.75 (0.25 to 4.00) |
| TAF: Third Trimester | 1.00 (0.25 to 3.00) |
| TAF: Week 6 Post-partum | 0.75 (0.25 to 3.00) |
| TAF: Week 12 Post-partum | 0.75 (0.25 to 3.00) |
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| h | B/F/TAF |
|---|---|
| BIC: Second Trimester | 9.09 (4.75 to 16.04) |
| BIC: Third Trimester | 9.91 (7.53 to 16.24) |
| BIC: Week 6 Post-partum | 18.24 (12.18 to 29.59) |
| BIC: Week 12 Post-partum | 17.27 (4.534 to 26.3) |
| FTC: Second Trimester | 6.43 (4.76 to 7.36) |
| FTC: Third Trimester | 6.41 (4.49 to 7.91) |
| FTC: Week 6 Post-partum | 6.27 (4.47 to 7.80) |
| FTC: Week 12 Post-partum | 5.76 (3.83 to 8.19) |
| TAF: Second Trimester | 0.30 (0.22 to 0.66) |
| TAF: Third Trimester | 0.28 (0.19 to 0.62) |
| TAF: Week 6 Post-partum | 0.40 (0.25 to 0.60) |
| TAF: Week 12 Post-partum | 0.35 (0.25 to 0.60) |
CLss/F is defined as the apparent steady-state oral clearance following administration of the drug.
| mL/h | B/F/TAF |
|---|---|
| BIC: Second Trimester | 911.78 ± 433.301 |
| BIC: Third Trimester | 902.47 ± 287.285 |
| BIC: Week 6 Post-partum | 399.02 ± 113.214 |
| BIC: Week 12 Post-partum | 362.40 ± 95.856 |
| FTC: Second Trimester | 20228.02 ± 3981.186 |
| FTC: Third Trimester | 19975.85 ± 4223.365 |
| FTC: Week 6 Post-partum | 12991.62 ± 3111.349 |
| FTC: Week 12 Post-partum | 13645.71 ± 2830.897 |
| TAF: Second Trimester | 122677.74 ± 44270.041 |
| TAF: Third Trimester | 135061.19 ± 44876.970 |
| TAF: Week 6 Post-partum | 76939.32 ± 29189.555 |
| TAF: Week 12 Post-partum | 92888.59 ± 29461.550 |
Vz/F is defined as the apparent volume of distribution of the drug.
| mL | B/F/TAF |
|---|---|
| BIC: Second Trimester | 11896.24 ± 4417.149 |
| BIC: Third Trimester | 13406.77 ± 4349.429 |
| BIC: Week 6 Post-partum | 10348.47 ± 3713.380 |
| BIC: Week 12 Post-partum | 8692.59 ± 2398.645 |
| FTC: Second Trimester | 181767.32 ± 36739.344 |
| FTC: Third Trimester | 184791.79 ± 56340.526 |
| FTC: Week 6 Post-partum | 117384.90 ± 35385.941 |
| FTC: Week 12 Post-partum | 117660.87 ± 33240.095 |
| TAF: Second Trimester | 62333.17 ± 37242.307 |
| TAF: Third Trimester | 53230.98 ± 16727.325 |
| TAF: Week 6 Post-partum | 44440.06 ± 13678.515 |
| TAF: Week 12 Post-partum | 49837.70 ± 22019.454 |
λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
| 1/h | B/F/TAF |
|---|---|
| BIC: Second Trimester | 0.077 ± 0.0231 |
| BIC: Third Trimester | 0.068 ± 0.0125 |
| BIC: Week 6 Post-partum | 0.040 ± 0.0098 |
| BIC: Week 12 Post-partum | 0.043 ± 0.0134 |
| FTC: Second Trimester | 0.113 ± 0.0142 |
| FTC: Third Trimester | 0.112 ± 0.0173 |
| FTC: Week 6 Post-partum | 0.114 ± 0.0151 |
| FTC: Week 12 Post-partum | 0.120 ± 0.0209 |
| TAF: Second Trimester | 2.227 ± 0.7128 |
| TAF: Third Trimester | 2.550 ± 0.7519 |
| TAF: Week 6 Post-partum | 1.777 ± 0.4685 |
| TAF: Week 12 Post-partum | 1.954 ± 0.4519 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of delivery was analyzed in B/F/TAF group using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at the Time of Delivery Using the Missing = Excluded Approach in B/F/TAF Group | 100.0 (89.1 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at the time of birth was analyzed in neonates using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
| percentage of participants | Neonates |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Birth Using the Missing = Excluded Approach in Neonates | 100.0 (15.8 to 100.0) |
Collected over All-Cause Mortality: From birth up to 8 weeks of age for neonates; From enrollment up to 38 weeks + 30 days for B/F/TAF group. Adverse Events: First dose date up to 38 weeks + 30 days for B/F/TAF group. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/F/TAF | 0/33 (0%) | 6/33 (18.2%) | 19/33 (57.6%) |
| Neonates | 0/29 (0%) | 5/29 (17.2%) | 4/29 (13.8%) |
| Event | B/F/TAF | Neonates |
|---|---|---|
| False labourPregnancy, puerperium and perinatal conditions | 3/33 | 0/29 |
| Accessory auricleCongenital, familial and genetic disorders | 0/33 | 1/29 |
| Atrial septal defectCongenital, familial and genetic disorders | 0/33 | 1/29 |
| Sepsis neonatalInfections and infestations | 0/33 | 1/29 |
| Jaundice neonatalPregnancy, puerperium and perinatal conditions | 0/33 | 1/29 |
| Neonatal asphyxiaRespiratory, thoracic and mediastinal disorders | 0/33 | 1/29 |
| Transient tachypnoea of the newbornRespiratory, thoracic and mediastinal disorders | 0/33 | 1/29 |
| Nonreassuring foetal heart rate patternCardiac disorders | 1/33 | 0/29 |
| PyrexiaGeneral disorders | 1/33 | 0/29 |
| Covid-19Infections and infestations | 1/33 | 0/29 |
| Event | B/F/TAF | Neonates |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 4/33 | 0/29 |
| Gestational diabetesPregnancy, puerperium and perinatal conditions | 4/33 | 0/29 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/33 | 3/29 |
| AnaemiaBlood and lymphatic system disorders | 3/33 | 0/29 |
| Jaundice neonatalPregnancy, puerperium and perinatal conditions | 0/33 | 2/29 |
| Foetal heart rate deceleration abnormalityCardiac disorders | 2/33 | 0/29 |
| Abdominal painGastrointestinal disorders | 2/33 | 0/29 |
| HaemorrhoidsGastrointestinal disorders | 2/33 | 0/29 |
| DizzinessNervous system disorders | 2/33 | 0/29 |
| HeadacheNervous system disorders | 2/33 | 0/29 |
B/F/TAF: Safety analysis set included all adult participants who took at least 1 dose of study drug (B/F/TAF). Neonates: Safety analysis set included neonates who were born to women participating in the study and had been enrolled into the study as well.
| Age, Continuous(years) | B/F/TAF | Neonates | Total |
|---|---|---|---|
| Mean | 30 ± 5.0 | 0 ± 0.0 | 16 ± 15.5 |
| Sex: Female, Male(Participants) | B/F/TAF | Neonates | Total |
|---|---|---|---|
| Female | 33 | 10 | 43 |
| Male | 0 | 19 | 19 |
| Ethnicity (NIH/OMB)(Participants) | B/F/TAF | Neonates | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 29 | 25 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | Neonates | Total |
|---|---|---|---|
| Race — Asian | 25 | 24 | 49 |
| Race — Black | 6 | 4 | 10 |
| Race — Other | 1 | 1 | 2 |
| Race — White | 1 | 0 | 1 |
| Region of Enrollment(Participants) | B/F/TAF | Neonates | Total |
|---|---|---|---|
| Thailand | 25 | 24 | 49 |
| United States | 5 | 2 | 7 |
| Dominican Republic | 3 | 3 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Jun 2019 to primary completion in Jul 2022, 36 months.
Results were first posted in May 2024, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide